Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Clinical trial NCT05422066 · UNKNOWN

Trial details

NCT number: NCT05422066
Sponsor: Li Zhiming
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

DLBCL Germinal Center B-Cell Type

Start date: 2022-07-26
Primary completion: 2025-07-30
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.